Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma?

被引：0
|
作者：
Andrew Jacobs
机构：
[1] Chief of Cancer Care Services and Medical Director of Clinical Research at the Benaroya Research Institute at Virginia Mason Medical Center,
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：424 / 425
页数：1
相关论文
共 50 条
  • [41] Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
    Shukuya, Takehito
    Yamanaka, Takeharu
    Seto, Takashi
    Daga, Haruko
    Goto, Koichi
    Saka, Hideo
    Sugawara, Shunichi
    Takahashi, Toshiaki
    Yokota, Soichiro
    Kaneda, Hiroyasu
    Kawaguchi, Tomoya
    Nagase, Seisuke
    Oguri, Tetsuya
    Iwamoto, Yasuo
    Nishimura, Takashi
    Hattori, Yoshihiro
    Nakagawa, Kazuhiko
    Nakanishi, Yoichi
    Yamamoto, Nobuyuki
    LANCET ONCOLOGY, 2015, 16 (16): : 1630 - 1638
  • [42] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Tannock, IF
    de Wit, R
    Berry, WR
    Horti, J
    Pluzanska, A
    Chi, KN
    Oudard, S
    Theodore, C
    James, ND
    Turesson, I
    Rosenthal, MA
    Eisenberger, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15): : 1502 - 1512
  • [43] A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel
    Cereda, S.
    Reni, M.
    Rognone, A.
    Ghidini, M.
    Rezzonico, S.
    Passoni, P.
    Mazza, E.
    Belli, C.
    Zerbi, A.
    Villa, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 365 - 365
  • [44] A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel
    Cereda, S.
    Rognone, A.
    Ghidini, M.
    Rezzonico, S.
    Passoni, P.
    Mazza, E.
    Nicoletti, R.
    Zerbi, A.
    Villa, E.
    Reni, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] A Multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer
    Fahlke, J.
    Ridwelski, K.
    Schmidt, C.
    Hribaschek, K.
    Stuebs, P.
    Kettner, E.
    Quietzsch, D.
    Assmann, M.
    Deist, T.
    Keilholz, U.
    Lippert, H.
    CHEMOTHERAPY, 2007, 53 (06) : 454 - 460
  • [46] Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer
    Luo, Haiqing
    Yu, Zhonghua
    Gao, Hongfei
    Guan, Chengnong
    Xu, Meng
    JOURNAL OF BUON, 2013, 18 (01): : 154 - 161
  • [47] Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
    del Muro, XG
    Marcuello, E
    Gumá, J
    Paz-Ares, L
    Climent, MA
    Carles, J
    Parra, MS
    Tisaire, JL
    Maroto, P
    Germá, JR
    BRITISH JOURNAL OF CANCER, 2002, 86 (03) : 326 - 330
  • [48] Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
    X García del Muro
    E Marcuello
    J Gumá
    L Paz-Ares
    M A Climent
    J Carles
    M Sánchez Parra
    J L Tisaire
    P Maroto
    J R Germá
    British Journal of Cancer, 2002, 86 : 326 - 330
  • [49] EFFECT OF DOCETAXEL (TXT) PLUS CISPLATIN (C) IN LOCALLY ADVANCED AND METASTATIC GASTRIC ADENOCARCINOMA
    Mahfouf, H.
    Haddouche, L.
    Belhadef, S.
    Djedi, H.
    Oukkal, M.
    Bentabak, K.
    Bouzid, K.
    ANNALS OF ONCOLOGY, 2009, 20 : 50 - 51
  • [50] An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma
    Miller, Eric J.
    Galsky, Matthew D.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (04) : 319 - 326
12345